Journal of Cancer Research and Therapeutics Close
 

Figure 2: The media progression-free survival was 11 months in the oligometastatic patients who received concurrent involved-field radiotherapy and XELOX

Figure 2: The media progression-free survival was 11 months in the oligometastatic patients who received concurrent involved-field radiotherapy and XELOX